NCT06209385View on ClinicalTrials.gov

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

October 31, 2027

Study Completion Date

January 31, 2028

Conditions
Solid Tumor
Interventions
DRUG

YZJ-5053 tablets

YZJ-5053 tablets will be administrated orally QD for 21 days

Trial Locations (4)

200120

RECRUITING

Shanghai East Hospital, Shanghai

250000

NOT_YET_RECRUITING

Shandong Cancer Hospital, Jinan

310000

NOT_YET_RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

330000

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

INDUSTRY